Skip to main content

Main menu

  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Blog
    • Collections
    • Podcast
  • TOPICS
    • Cognition and Behavior
    • Development
    • Disorders of the Nervous System
    • History, Teaching and Public Awareness
    • Integrative Systems
    • Neuronal Excitability
    • Novel Tools and Methods
    • Sensory and Motor Systems
  • ALERTS
  • FOR AUTHORS
  • ABOUT
    • Overview
    • Editorial Board
    • For the Media
    • Privacy Policy
    • Contact Us
    • Feedback
  • SUBMIT

User menu

Search

  • Advanced search
eNeuro
eNeuro

Advanced Search

 

  • HOME
  • CONTENT
    • Early Release
    • Featured
    • Current Issue
    • Issue Archive
    • Blog
    • Collections
    • Podcast
  • TOPICS
    • Cognition and Behavior
    • Development
    • Disorders of the Nervous System
    • History, Teaching and Public Awareness
    • Integrative Systems
    • Neuronal Excitability
    • Novel Tools and Methods
    • Sensory and Motor Systems
  • ALERTS
  • FOR AUTHORS
  • ABOUT
    • Overview
    • Editorial Board
    • For the Media
    • Privacy Policy
    • Contact Us
    • Feedback
  • SUBMIT
PreviousNext
Research ArticleResearch Article: New Research, Sensory and Motor Systems

Pregabalin Silences Oxaliplatin-Activated Sensory Neurons to Relieve Cold Allodynia

Federico Iseppon, Ana P. Luiz, John E. Linley and John N. Wood
eNeuro 31 January 2023, 10 (2) ENEURO.0395-22.2022; https://doi.org/10.1523/ENEURO.0395-22.2022
Federico Iseppon
1Molecular Nociception Group, Wolfson Institute for Biomedical Research, University College London, London WC1E 6BT, United Kingdom
2Discovery UK, Neuroscience, Biopharmaceuticals R&D, AstraZeneca, Cambridge CB21 6GH, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ana P. Luiz
1Molecular Nociception Group, Wolfson Institute for Biomedical Research, University College London, London WC1E 6BT, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John E. Linley
2Discovery UK, Neuroscience, Biopharmaceuticals R&D, AstraZeneca, Cambridge CB21 6GH, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John N. Wood
1Molecular Nociception Group, Wolfson Institute for Biomedical Research, University College London, London WC1E 6BT, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Figures & Data

Figures

  • Extended Data
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Assessment of the effect of pregabalin on acute oxaliplatin-induced cold allodynia. A, Cold-plate assessment at 10°C of mice treated with oxaliplatin and successively either vehicle or 2 mg/kg of pregabalin. Activity was measured as the total number of nociceptive behaviors (hindpaw lifts, shakes, licks) over the test duration. A cutoff time of 300 s was used to limit tissue damage. The baseline data in the graph refers to the mice injected with oxaliplatin. For the baseline versus oxaliplatin-treated animal data please refer to Extended Data Figure 1-1. B, Plot showing the decrease of the number of nociceptive behaviors over time following vehicle or pregabalin injection. C, Cold-plate assessment at 10°C of mice treated only with pregabalin. Activity was measured as the total number of forepaw lifts over the test duration. A cutoff time of 300 s was used to limit tissue damage. n = 8 oxaliplatin + pregabalin mice, n = 8 oxaliplatin + vehicle mice, n = 6 pregabalin only mice. Statistical analyses in A and B were performed using one-way and two-way ANOVA tests with multiple comparisons, respectively. Statistical Analysis in C was performed using paired t test. *p < 0.05, **p < 0.01, ***p < 0.001.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Pregabalin treatment decreases both the number of neurons responding to cold stimuli and the intensity of their responses. A, Example images showing the reduction in the population of DRG neurons responding to ice-water 50 min after treatment with 2 mg/kg of pregabalin. B, Graph showing the decrease of the percentages of cell responding to ice-water stimulus. C, Example traces showing the decrease in the intensity of the calcium signals over time from pregabalin injection. D, Plot showing the mean response amplitude before (black trace) and 40 min (blue) and 50 min (pink) after pregabalin injection. n = 45 cells for all time points. E, Graphs showing the ΔFmax changes before and 40 and 50 min after pregabalin injection. F, Graphs showing the area under curve changes before and 40 and 50 min after pregabalin injection. n = 6 pregabalin-treated mice, n = 5 vehicle-treated mice. Statistical analysis in B was performed using repeated measures ANOVA test with multiple comparisons. Statistical analysis in D was performed using multiple Wilcoxon tests. Statistical analyses in E and F were performed using one-way ANOVA. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. For the data regarding acetone, hot water, and mechanical stimulations please refer to Extended Data Figures 2-1 and 2-2.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Pregabalin treatment significantly reduces the excitability of cold responding cells and targets preferentially medium-large mechano-cold sensors. A, Example traces of a representative cold-sensing cell in response to a series of 4°C temperature drops from a holding temperature of 32°C. The traces represent the change in the threshold of this neuron over time (0–50 min) from pregabalin injection. Arrowheads mark the first response to temperature drops in every timepoint. B, Graph showing the change of the relationship between the number of cold-responding neurons and the temperature drop over time from pregabalin injection. While the relationship at baseline can be fit with a linear equation (y = −3.292× + 99.84; r2 = 0.9880; n = 115), the one at 50-min fits a quadratic equation (y = 110.8 − 7.381× + 0.1265x2; r2 = 0.9927; n = 109). The slopes at baseline and 50 min after treatment are significantly different (***p < 0.001), as analyzed by Wilcoxon test. For a complete visualization of the data regarding the cold threshold changes in all time points please refer to Extended Data Figure 3-1. C, Graphs showing the change in the number of total mechano-responding neurons that respond also to ice-water stimulus. Mice treated with vehicle do not exhibit the decrease over time from treatment as the mice treated with pregabalin do. For the graphs showing the mechano-acetone and mechano-heat responding cells trends please refer to Extended Data Figure 3-2. D, Numeric plots of the distribution of cold-responding cell areas in oxaliplatin-treated mice before (black trace) and after 50 min (pink trace) from pregabalin injection. The difference between the distributions at different timepoints after treatment is statistically significant (***p = 0.0001), as analyzed by Wilcoxon test. For a complete visualization of the numeric distributions of cold responding cells areas in all time points please refer to Extended Data Figure 3-3. n = 7 mice for temperature threshold experiments; n = 6 pregabalin-treated mice, n = 5 vehicle-treated mice.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Knock-out of the α2δ1 subunit of the VGCCs is sufficient to abolish the effects of pregabalin both on cold allodynia and on silencing of cold responding DRG neurons. A, Plot showing the decrease of the number of nociceptive behaviors over time from vehicle (n = 8; black trace) or pregabalin injection in WT [n = 8 (blue trace) + 10 (light blue trace)] and α2δ1-KO mice (n = 10; red trace) when exposed to a 10°C cold plate for 5 min (**p < 0.01). B, Example images showing that the reduction of the population of DRG neurons responding to ice-water 50 min after treatment with pregabalin is absent in α2δ1-KO mice. C, Graph showing the disappearance of the decrease of the percentages of cell responding to ice-water stimulus in α2δ1-KO mice. Change is quantified as fold-change to baseline. D, Numeric plots of the distribution of cold responding cell areas in oxaliplatin-treated α2δ1-KO mice before (gray trace) and 50 min after pregabalin injection (light pink trace). n = 7 α2δ1-KO mice, n = 6 pregabalin-treated mice, n = 5 vehicle-treated mice for imaging data. Statistical analyses in C were performed using repeated measures ANOVA test with multiple comparisons. *p < 0.05 (WT vehicle vs WT pregabalin treated); ##p < 0.01 (α2δ1-KO vs WT pregabalin treated). For the data regarding acetone, hot water, and mechanical responses, please refer to Extended Data Figure 4-1. For the data regarding the area distribution of cold responding cells after pregabalin treatment in α2δ1-KO animals, please refer to Extended Data Figure 4-2.

Extended Data

  • Figures
  • Extended Data Figure 1-1

    Assessment of cold allodynia after injection of oxaliplatin. Cold-plate assessment at 10°C of mice treated with oxaliplatin. Activity was measured as the total number of nociceptive behaviors (shaking, lifting, licking, guarding, biting) over the test duration. A cutoff time of 300 s was used to limit tissue damage. n = 10 oxaliplatin-treated mice. Statistical analysis was performed using paired t test. ****p < 0.0001. Download Figure 1-1, TIF file.

  • Extended Data Figure 2-1

    Pregabalin treatment decreases the number of neurons responding to a chemical cold stimulus. A, Example images showing the reduction in the population of DRG neurons responding to acetone 50 min after treatment with 2 mg/kg of pregabalin. B, Graph showing the decrease of the percentages of cell responding to acetone. n = 6 pregabalin-treated mice, n = 5 vehicle-treated mice. Statistical analysis in B was performed using repeated measures ANOVA test with multiple comparisons. *p < 0.05, **p < 0.01. Download Figure 2-1, TIF file.

  • Extended Data Figure 2-2

    Pregabalin treatment does not affect other sensory modalities besides cold. A, Example images showing no change in the population of DRG neurons responding to mechanical pinch 50 min after treatment with 2 mg/kg of pregabalin. B, Graph showing the unchanged percentages of cell responding to mechanical pinch. C, Example images showing no change in the population of DRG neurons responding to a 55°C water stimulus 50 min after treatment with 2 mg/kg of pregabalin. D, Graph showing the unchanged percentages of cell responding to a 55°C water stimulus. n = 6 pregabalin-treated mice, n = 5 vehicle-treated mice. Statistical analysis in B and D was performed using repeated measures ANOVA test with multiple comparisons. Download Figure 2-2, TIF file.

  • Extended Data Figure 3-1

    Pregabalin treatment increases temperature threshold of cold-responding cells over time. Graph showing the change of the relationship between the number of cold-responding neurons and the temperature drop over time from pregabalin injection. Download Figure 3-1, TIF file.

  • Extended Data Figure 3-2

    Pregabalin treatment reduces the number of polymodal mechano-cold but not mechano-heat responding cells. A, Graph showing the change in the number of total mechano-responding neurons that respond also to acetone stimulus. Mice treated with vehicle do not exhibit the decrease over time from treatment as the mice treated with pregabalin do. B, Graph showing the change in the number of total mechano-responding neurons that respond also to a 55°C water stimulus. Mice do not exhibit significant differences in the percentage of polymodal mechano-heat responding neurons over time from pregabalin treatment. n = 6 pregabalin-treated mice, n = 5 vehicle-treated mice. Download Figure 3-2, TIF file.

  • Extended Data Figure 3-3

    Pregabalin preferentially inhibits the activity of “silent” cold-sensing neurons. A, Cumulative plots of the cell areas in oxaliplatin-treated mice before and after pregabalin injection. The difference between the distributions at different timepoints after treatment is statistically significant (p < 0.0001), as analyzed by Kruskal–Wallis test. B, Number plots of the distribution of cell areas of cold-responding cells in oxaliplatin-treated mice before and after pregabalin injection. The difference between the numeric distributions at different timepoints after treatment is statistically significant (p < 0.0001), as analyzed by Kruskal–Wallis test. C, Graph showing the area under curve changes before and 50 min after pregabalin injection. The cell areas are divided into basal cold responding cells (A < 480 μm2) and silent cold sensors (A > 480 μm2). Albeit there is a difference in both populations after 50 min from treatment, the population of silent cold sensors seems to be silenced almost completely. These thresholds have been calculated previously (MacDonald et al., 2021). Download Figure 3-3, TIF file.

  • Extended Data Figure 4-1

    Knock-out of the α2δ1 subunit of the VGCCs abolishes the effects of pregabalin on cold but has no effect on heat and mechanical responses. A, Example images showing no change in the population of DRG neurons responding to acetone, 55°C water, and mechanical pinch 50 min after treatment of α2δ1-KO mice with 2 mg/kg of pregabalin. B, Graph showing the unchanged percentages of cell responding to acetone in α2δ1-KO mice with respect to WT ones. C, Graph showing the unchanged percentages of cell responding to a 55°C water stimulus in α2δ1-KO mice with respect to WT ones. D, Graph showing the unchanged percentages of cell responding to mechanical pinch in α2δ1-KO mice with respect to WT ones. n = 7 α2δ1-KO mice, n = 6 pregabalin-treated mice, n = 5 vehicle-treated mice for imaging data. Statistical analyses in B–D were performed using repeated measures ANOVA test with multiple comparisons. ##p < 0.01 (α2δ1-KO vs WT pregabalin treated). Download Figure 4-1, TIF file.

  • Extended Data Figure 4-2

    Knock-out of the α2δ1 subunit of the VGCCs abolishes the silencing effect of pregabalin on silent cold sensors. Graph showing the area under curve changes before and 50 min after pregabalin injection in the α2δ1-KO mice. The cell areas are divided into basal cold responding cells (A < 480 μm2) and silent cold sensors (A > 480 μm2). There seems to be no difference in the population of basal and silent cold sensors after pregabalin treatment when the α2δ1 subunit is knocked down globally. These thresholds have been calculated previously (MacDonald et al., 2021). Download Figure 4-2, TIF file.

Back to top

In this issue

eneuro: 10 (2)
eNeuro
Vol. 10, Issue 2
February 2023
  • Table of Contents
  • Index by author
  • Masthead (PDF)
Email

Thank you for sharing this eNeuro article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Pregabalin Silences Oxaliplatin-Activated Sensory Neurons to Relieve Cold Allodynia
(Your Name) has forwarded a page to you from eNeuro
(Your Name) thought you would be interested in this article in eNeuro.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
View Full Page PDF
Citation Tools
Pregabalin Silences Oxaliplatin-Activated Sensory Neurons to Relieve Cold Allodynia
Federico Iseppon, Ana P. Luiz, John E. Linley, John N. Wood
eNeuro 31 January 2023, 10 (2) ENEURO.0395-22.2022; DOI: 10.1523/ENEURO.0395-22.2022

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Pregabalin Silences Oxaliplatin-Activated Sensory Neurons to Relieve Cold Allodynia
Federico Iseppon, Ana P. Luiz, John E. Linley, John N. Wood
eNeuro 31 January 2023, 10 (2) ENEURO.0395-22.2022; DOI: 10.1523/ENEURO.0395-22.2022
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Significance Statement
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
    • Synthesis
    • Author Response
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Keywords

  • oxaliplatin
  • pain
  • pregabalin
  • sensory neurons
  • silent nociceptors

Responses to this article

Respond to this article

Jump to comment:

No eLetters have been published for this article.

Related Articles

Cited By...

More in this TOC Section

Research Article: New Research

  • Multiplexed smFISH reveals the spatial organization of neuropil localized mRNAs is linked to abundance
  • Novelty influences dopamine responses to conditioned and unconditioned aversive stimuli over extended temporal windows
  • Ionotropic glutamate receptor function in interpeduncular nucleus is modulated by nicotine exposure
Show more Research Article: New Research

Sensory and Motor Systems

  • Spatially Extensive LFP Correlations Identify Slow-Wave Sleep in Marmoset Sensorimotor Cortex
  • What Is the Difference between an Impulsive and a Timed Anticipatory Movement?
  • Odor Experience Stabilizes Glomerular Output Representations in Two Mouse Models of Autism
Show more Sensory and Motor Systems

Subjects

  • Sensory and Motor Systems
  • Home
  • Alerts
  • Follow SFN on BlueSky
  • Visit Society for Neuroscience on Facebook
  • Follow Society for Neuroscience on Twitter
  • Follow Society for Neuroscience on LinkedIn
  • Visit Society for Neuroscience on Youtube
  • Follow our RSS feeds

Content

  • Early Release
  • Current Issue
  • Latest Articles
  • Issue Archive
  • Blog
  • Browse by Topic

Information

  • For Authors
  • For the Media

About

  • About the Journal
  • Editorial Board
  • Privacy Notice
  • Contact
  • Feedback
(eNeuro logo)
(SfN logo)

Copyright © 2025 by the Society for Neuroscience.
eNeuro eISSN: 2373-2822

The ideas and opinions expressed in eNeuro do not necessarily reflect those of SfN or the eNeuro Editorial Board. Publication of an advertisement or other product mention in eNeuro should not be construed as an endorsement of the manufacturer’s claims. SfN does not assume any responsibility for any injury and/or damage to persons or property arising from or related to any use of any material contained in eNeuro.